Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617403 | 0.78 | PSEN1 (0.44) | CYP1A2ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL1617435 | 0.78 | PSEN1 (0.45) | CYP1A2KDM4EPSEN1PSEN2APH1B | |
| SCHEMBL27985278 | 0.78 | CYP1A2 (0.65) | PTK2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1450033 | 0.77 | PTK2 (0.56) | PTK2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL962517 | 0.76 | PSEN1 (0.57) | CYP3A4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1039865 | 0.75 | PSEN1 (0.47) | CYP1A2NR2E1KDM4EPSEN1PSEN2 | |
| SCHEMBL1041288 | 0.73 | PSEN1 (0.46) | CYP3A4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL264998 | 0.73 | CYP1A2 (0.56) | PTK2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12988609 | 0.73 | CYP3A4 (0.56) | PTK2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3712352 | 0.73 | PDE4A (0.58) | PTK2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910142-B | Modulators for beta-amyloid | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| CN-101675045-B | Hetarylanilines as modulators for amyloid beta | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | disclosed |
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7910740-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2155740-B1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-01-26 | — | — | EP | disclosed |
| CN-101910142-A | The conditioning agent of amyloid beta | HOFFMANN LA ROCHE | 2010-12-08 | — | — | CN | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| CN-101675045-A | Hetarylanilines as modulators for amyloid beta | HOFFMANN LA ROCHE | 2010-03-17 | — | — | CN | disclosed |
| EP-2155740-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2008138753-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | PTK2 3473/4885CYP3A4 4634/4885CYP2D6 3751/4885 |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | PTK2 2222/4885CYP3A4 531/4885CYP2D6 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.